-
A Study to Evaluate KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis
Rochester, MN
The purpose of this study is to evaluate the effectiveness and safety of KD025 in patients with diffuse cutaneous systemic sclerosis. Upon eligibility confirmation, a total of sixty (60) adult subjects will be enrolled and randomized into three (3) groups (1:1:1) to either receive orally administered KD025 (two doses) or matched placebo for 28 weeks. The study will be double-blinded for the first 28 weeks followed by an open label extension period of 24 weeks. After un-blinding, the subjects on KD025 will continue on the same KD025 dose whereas the subjects in the placebo group will be re-randomized to one of ...
-
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Rochester, MN
The purpose of this study is to assess the safety and effectiveness of subcutaneous abatacept in patients with diffuse cutaneous systemic sclerosis.
-
Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis
Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate the effectiveness and safety of KD025 to treat Diffuse Cutaneous Systemic Sclerosis.
-
A Study to Evaluate Cardiopulmonary Complications in Systemic Sclerosis
Rochester, MN
The purpose of this study is to assess whether our not the percentage of pulmonary related vascular structures (PRVS) determined by the quantitative CT (Q-CT) tool CALIPER is a novel measure that can be used for the early detection of pulmonary vascular remodeling in patients with SSc. pulmonary related vascular structures
-
A Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
Jacksonville, FL
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).